Qiagen is leaning into faster, more automated lab workflows and easier software tools, aiming to turn more testing and research into steady repeat sales over time. The upside depends on whether demand in research labs and key markets recovers before tougher competition and deal-making missteps squeeze growth.Read more
Qiagen could get a fresh lift as doctors expand screening for a hard-to-spot form of tuberculosis and labs adopt faster, more automated testing workflows. But weaker demand tied to immigration testing and cautious research spending could still hold back results if new products and software don’t ramp as hoped.Read more
Qiagen’s growth story leans heavily on new testing systems and lab software, but a slowdown in lab spending and shifting immigration testing demand could keep progress bumpy in the near term. See what would need to go right for its newer platforms to pick up the slack—and what could hold the business back if budgets and policy stay tight.Read more
No trending discussion available.
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
